Pandemic Latest News

Maiden Pharma’s license suspended following cough syrup deaths

Indian authorities have suspended the licence of Delhi-based drugmaker, Maiden Pharma, after it failed to furnish information on cough syrup related deaths in West Africa’s The Gambia.
The company is accused of supplying cough syrup that led to the deaths of 66 children in The Gambia.
Meanwhile, police in The Gambia are investigating the deaths of 66 children, which have been linked to four brands of imported Indian cough syrup.
Senior officials from the Medicine Control Agency and the importers have been called for questioning, the president’s office said.
President Adama Barrow said that the authorities would “leave no stone unturned” in the investigation.
Gambians, angry about what happened, are wondering who is to blame.
On Wednesday, the World Health Organization (WHO) issued a global alert over the four cough syrups – warning they could be linked to acute kidney injuries and the children’s deaths in July, August and September.
Bereaved parents have told the BBC how their children stopped being able to pass urine after being given the syrups. As their condition worsened, efforts to save their lives were fruitless.
The products – Promethazine Oral Solution, Kofexmalin Baby Cough Syrup, Makoff Baby Cough Syrup and Magrip N Cold Syrup – were manufactured by an Indian company, Maiden Pharmaceuticals, which had failed to provide guarantees about their safety, the WHO said.

Leave a Comment

Your email address will not be published. Required fields are marked *